Form 4: Myriad Genetics Executive Mark Verratti Reports Share Withholdings for Tax Obligations

Chief Commercial Officer Mark Verratti of Myriad Genetics reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Summary

• Mark Verratti, Chief Commercial Officer of Myriad Genetics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates that shares of common stock were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units and performance-based restricted stock units.
• These transactions occurred on March 22, 2025, and March 24, 2025.
• The prices at which the shares were withheld were $10.01 on March 22 and $9.98 on March 24.
• Following these transactions, Verratti directly owns 383,996 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing (Form 4) detailing share withholdings for tax purposes. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. It is a neutral event.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard tax-related share withholdings, which are common when restricted stock units vest.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they relate to tax obligations of an executive.

Key Dates

Keywords

Form 4, Beneficial Ownership, Myriad Genetics, Verratti, Tax Withholding, Restricted Stock Units, MYGN, Shares